Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: A report from the intergroup rhabdomyosarcoma study group

Medical and Pediatric Oncology

Volumn 37, Issue 5, 2001, Pages 442-448

  Sandler, E ^a   Lyden, E ^a   Ruymann, F ^a   Maurer, H ^a   Wharam, M ^a   Parham, D ^a   Link, M ^a   Crist, W ^a  

^a CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

Doxorubicin; Ifosfamide; IRSG; Rhabdomyosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; IFOSFAMIDE; MESNA; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG INDUCED DISEASE; FEMALE; HUMAN; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RHABDOMYOSARCOMA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DOXORUBICIN; FEMALE; HUMANS; IFOSFAMIDE; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; NEOPLASM METASTASIS; RHABDOMYOSARCOMA; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034764658     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.1227     Document Type: Article

References (29)

1. Does debulking improve survival rate in advanced-stage retroperitoneal embryonal Rhabdomyosarcoma?
2. Review article-Biology and therapy of pediatric rhabdomyosarcoma
3. Rhabdomyosarcoma of childhood
4. The third intergroup rhabdomyosarcoma study
5. The Intergroup Rhabdomyosarcoma Study-I
6. The Intergroup Rhabdomyosarcoma Study-II
7. Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas
8. Chemotherapy of sarcomas - A perspective
9. Childhood rhabdomyosarcoma xenografts: Responses to DNA-interacting agents and agents used in current clinical therapy
10. Adriamycin in pediatric malignancies
11. A feasibility, toxicity, and efficacy study of ifosfamide, actinomycin D and vincristine for the treatment of childhood rhabdomyosarcoma
12. A feasibility, toxicity, and early response study of etoposide, ifosfamide, vincristine for the treatment of children with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study (IRS) IV Pilot Study
13. Nonparametric estimation from incomplete observations
14. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: Analysis and examples
15. Adriamycin-an anti-tumor antibiotic in the treatment of neoplastic diseases
16. Drug sensitivity and resistance in the xenograft model
17. Phase II study of adriamycin in childhood solid tumors
18. Adriamycin in the treatment of childhood solid tumors
19. Cardiac toxicity 4 to 20 years after completing anthracycline therapy
20. Strategies for reduction of anthracycline cardiac toxicity
21. Ameliorating anthracycline cardiotoxicity in children with cancer: Clinical trials with dexrazoxane
22. Ifosfamide in pediatric malignant solid tumors
23. A Phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma
24. A Phase II study of ifosfamide in the treatment of recurrent sarcomas in young people
25. Comparison of the rates of response to ifosfamide and cyclophosphamide in primary unresectable rhabdomyosarcomas
26. Results of treatment of rhabdomyosarcoma in the European studies
27. Ifosfamide: Current aspects and perspectives
28. Ifosfamide: With mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults
29. Renal toxicity of ifosfamide in pilot regimens of the Intergroup Rhabdomyosarcoma Study for Patients with gross residual tumor